Cefazolin was found safer, and at least non-inferior and probably superior to cloxacillin or flucloxacillin in treating methicillin-susceptible S aureus bacteremia (MSSA), in a meta-analysis of the 2 randomized clinical trials that have directly compared the drug classes.1 "Taken together with the other advantages of cefazolin, including its longer half-life, tolerability and potential for use in patients with penicillin allergy, we believe the data supports cefazolin being preferred for adults with MSSA bacteremia," declare Todd Lee, MD, MPH, Division of Infectious Diseases, Department of Medicine, McGill University, Montréal, Canada, and colleagues.
In accompanying commentary, Michihiko Goto, MD, MS, Center for Access & Delivery Research and Evaluation (CADRE), Iowa City VA Health Care System, Iowa City, IA, credits the randomized trials and meta-analysis for addressing a long standing absence of comparative data that has left clinicians wondering whether cefazolin "is at least as good."2
"Few questions in clinical infectious diseases have been debated for so long with so little reliable clinical data as the choice of ß-lactam for MSSA bacteremia," Goto remarked.
The two trials that compared the classes are the French Cloxacillin vs Cefazolin for MSSA Bacteremia (CloCeBa) trial, and the International S aureus Network Adaptive Platform (SNAP) trial, together comprising approximately 1600 patients. 3,4
Goto points out a particular difference in the trial designs: the SNAP trial enrolled only patients with penicillin-resistant MSSA, while the CloCeBa included patients with MSSA irrespective of penicillin susceptibility.The noninferiority of cefazolin in the CloCeBa trial, he notes, was therefore demonstrated in a population that theoretically disadvantages it.